ATE535529T1 - Verfahren zur acylierung von maytansinol mit chiralen aminosäuren - Google Patents
Verfahren zur acylierung von maytansinol mit chiralen aminosäurenInfo
- Publication number
- ATE535529T1 ATE535529T1 AT06800952T AT06800952T ATE535529T1 AT E535529 T1 ATE535529 T1 AT E535529T1 AT 06800952 T AT06800952 T AT 06800952T AT 06800952 T AT06800952 T AT 06800952T AT E535529 T1 ATE535529 T1 AT E535529T1
- Authority
- AT
- Austria
- Prior art keywords
- maytansinol
- acylation
- amino acids
- chiral amino
- chiral
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- QWPXBEHQFHACTK-RZKXNLMUSA-N CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](O)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-RZKXNLMUSA-N 0.000 title 1
- QWPXBEHQFHACTK-UHFFFAOYSA-N Maytansinol Natural products CN1C(=O)CC(O)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 QWPXBEHQFHACTK-UHFFFAOYSA-N 0.000 title 1
- 230000010933 acylation Effects 0.000 title 1
- 238000005917 acylation reaction Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000006345 epimerization reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70669405P | 2005-08-09 | 2005-08-09 | |
| PCT/US2006/030857 WO2007021674A2 (en) | 2005-08-09 | 2006-08-08 | Method of acylating maytansinol with chiral amino acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE535529T1 true ATE535529T1 (de) | 2011-12-15 |
Family
ID=37758086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06800952T ATE535529T1 (de) | 2005-08-09 | 2006-08-08 | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7598375B2 (de) |
| EP (1) | EP1913002B9 (de) |
| JP (1) | JP5167130B2 (de) |
| AT (1) | ATE535529T1 (de) |
| AU (1) | AU2006280146B2 (de) |
| CA (1) | CA2617953C (de) |
| WO (1) | WO2007021674A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
| EP2126127B1 (de) | 2007-01-25 | 2016-09-28 | Dana-Farber Cancer Institute, Inc. | Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten |
| CA2680854C (en) | 2007-03-15 | 2017-02-14 | Ludwig Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
| ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| ATE543835T1 (de) | 2007-07-16 | 2012-02-15 | Genentech Inc | Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren |
| US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
| PT2247620T (pt) | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| CA2757382A1 (en) | 2009-04-01 | 2010-10-21 | Kristi Elkins | Anti-fcrh5 antibodies and immunoconjugates |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| KR20140010076A (ko) | 2011-02-15 | 2014-01-23 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| MX350954B (es) | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
| ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| BR112015006505B1 (pt) * | 2012-09-26 | 2022-03-15 | Immunogen, Inc | Métodos de preparo de intermediários na síntese de maitansinoides |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| CN103254213B (zh) * | 2012-12-21 | 2015-02-25 | 百奥泰生物科技(广州)有限公司 | 类美登素酯的制备方法及用于所述方法的组合物 |
| CN103288957B (zh) | 2012-12-21 | 2015-01-28 | 百奥泰生物科技(广州)有限公司 | 一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途 |
| EP2948478B1 (de) | 2013-01-25 | 2019-04-03 | Amgen Inc. | Antikörper gegen cdh19 für melanome |
| HK1219422A1 (zh) | 2013-02-28 | 2017-04-07 | Immunogen, Inc. | 包含细胞结合剂及细胞毒素剂的轭合物 |
| EP3964237B1 (de) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologisch aktive moleküle, konjugate davon und therapeutische verwendungen davon |
| SG11201508829QA (en) | 2013-05-30 | 2015-12-30 | Biogen Ma Inc | Oncostatin m receptor antigen binding proteins |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN105585579A (zh) * | 2014-10-24 | 2016-05-18 | 南京联宁生物制药有限公司 | 一种化合物及其制备方法以及美登素dm1的制备方法 |
| CN104623687B (zh) * | 2015-03-11 | 2017-09-05 | 中国科学院上海高等研究院 | 利用美登醇制备的抗体药物偶联物及其制备方法和应用 |
| MX376146B (es) | 2015-03-17 | 2025-03-07 | Regeneron Pharma | Reactivos de acilacion de aminoacidos y metodos para usar los mismos. |
| KR20240142591A (ko) | 2015-03-27 | 2024-09-30 | 리제너론 파아마슈티컬스, 인크. | 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법 |
| TW201711702A (zh) | 2015-06-04 | 2017-04-01 | 應克隆公司 | 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法 |
| CN113710674B (zh) * | 2019-04-18 | 2024-03-15 | 意迪那有限公司 | 制备含硫醇或二硫化物的美登素酯及其中间体的非对映选择性方法 |
| EP4587445A1 (de) * | 2022-09-16 | 2025-07-23 | ImmunoGen, Inc. | Verbesserte verfahren zur herstellung von maytansinol-n-methylalaninestern |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260609A (en) * | 1977-06-01 | 1981-04-07 | Merck & Co., Inc. | Di- and tri- substituted thiazoles |
| JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| BR0308090A (pt) * | 2002-03-01 | 2006-04-11 | Univ Tulane | conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos |
| US7301019B2 (en) * | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
-
2006
- 2006-08-08 AU AU2006280146A patent/AU2006280146B2/en active Active
- 2006-08-08 EP EP06800952A patent/EP1913002B9/de active Active
- 2006-08-08 JP JP2008526125A patent/JP5167130B2/ja active Active
- 2006-08-08 AT AT06800952T patent/ATE535529T1/de active
- 2006-08-08 CA CA2617953A patent/CA2617953C/en active Active
- 2006-08-08 US US11/500,378 patent/US7598375B2/en active Active
- 2006-08-08 WO PCT/US2006/030857 patent/WO2007021674A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP5167130B2 (ja) | 2013-03-21 |
| WO2007021674A2 (en) | 2007-02-22 |
| WO2007021674A3 (en) | 2007-07-26 |
| EP1913002A2 (de) | 2008-04-23 |
| EP1913002B1 (de) | 2011-11-30 |
| CA2617953C (en) | 2013-12-17 |
| CA2617953A1 (en) | 2007-02-22 |
| EP1913002A4 (de) | 2010-10-27 |
| AU2006280146B2 (en) | 2012-06-28 |
| AU2006280146A1 (en) | 2007-02-22 |
| US20070037972A1 (en) | 2007-02-15 |
| US7598375B2 (en) | 2009-10-06 |
| JP2009504655A (ja) | 2009-02-05 |
| EP1913002B9 (de) | 2012-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1913002A4 (de) | Verfahren zur acylierung von maytanisol mit chiralen aminosäuren | |
| DE602005011656D1 (de) | Verfahren zur behandlung von dickdarmkrebs mit botulinum neurotoxin | |
| ATE475419T1 (de) | Verfahren zur zubereitung von lansoprazol | |
| DE602004032160D1 (de) | Verfahren zur Zubereitung von Getränken | |
| DE602004002519D1 (de) | Verfahren zur Oberflächenbehandlung von Metallen | |
| EP1912674B8 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| ATE464908T1 (de) | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern | |
| DE60321130D1 (de) | Variation von parametern zur neurostimulation | |
| DE502004001613D1 (de) | Verfahren zur herstellung von polyamiden | |
| DE602005019144D1 (de) | Verfahren zur schmerzbehandlung in knochenkrebs du | |
| ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
| DE602004000313D1 (de) | Verfahren zur Verfügungstellung von ozonenthaltendem Wasser | |
| DE60325381D1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
| DE602004020895D1 (de) | Verfahren zur herstellung von kohlenstoffnanospulen | |
| DE10390418D2 (de) | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen | |
| DE502004005626D1 (de) | Verfahren zur herstellung von organoacylphosphiten | |
| EP1899472A4 (de) | Geänderter glyoxylat-shunt zur verbesserten produktion von aspartat abgeleiteter aminosäuren und chemikalien | |
| DE60331111D1 (de) | Verfahren zur Herstellung von martensitaushärtendem Stahl | |
| EP1888106A4 (de) | Zusammensetzungen und verfahren zur behandlung von ephrinsignalisierung mit cupredoxinen | |
| ATE456666T1 (de) | Verfahren zur auswertung von ribonukleotidsequenzen | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| ATA14432002A (de) | Verbessertes verfahren zur singlet sauerstoff oxidation von organischen substraten | |
| WO2005009361A3 (en) | Method of treating hit patients with argatroban | |
| ATE468032T1 (de) | Verfahren zur verringerung von herbheit |